GRAVITAS-119: Phase I Study of Itacitinib Plus Calcineurin Inhibitors as Prophylaxis for GVHD

Clinical Care Options (CCO) expert faculty Guy Young, MD, on the evolution of prophylaxis therapy for hemophilia A and adherence challenges with young adult patients

Guy A. Young, MD Released: September 22, 2021

Clinical commentary from European hematology experts on key clinical trials presented at the virtual EHA 2021 meeting, from Clinical Care Options (CCO)

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci María-Victoria Mateos, MD, PhD Lydia Scarfò, MD Ali T. Taher, MD, PhD, FRCP Released: July 28, 2021

Downloadable slideset with highlights from key blood cancers and nonmalignant blood disorders as presented at EHA Virtual Congress 2021, from Clinical Care Options (CCO)

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci María-Victoria Mateos, MD, PhD Lydia Scarfò, MD Ali T. Taher, MD, PhD, FRCP Released: July 16, 2021

Dr. Corey S. Cutler shares his views on current and future graft-vs-host disease (GVHD) therapies in this commentary from Clinical Care Options (CCO)

Corey S. Cutler, MD, MPH, FRCPC Released: April 27, 2021